Table 2 Antitumor efficacy of the experimental formulation of LCS 1269 for LLC

s.c.

60/24 × 5

78*

78*

66*

61*

45

58*

34*

0

100/2 × 96

80*

75*

69*

64*

64*

68*

15*

0

120/2 × 96

86*

79*

72*

71*

64*

63*

19*

0

per os

130/24 × 5

64*

56*

52*

31*

35*

24

–

0

150/24 × 5

69*

64*

61*

44*

42*

43*

13*

0

200/24 × 5

45*

56*

48*

41*

28

45*

–

0

i.v.

60/24 × 5

94*

68*

57*

61*

56*

51*

11*

0

70/24 × 5

96*

86*

80*

81*

61*

77*

8*

0

80/24 × 5

71*

76*

60*

54*

39*

71*

9*

0

150 × 1

81*

49*

24

35

13

27

–

0

180 × 1

–

–

–

–

–

–

–

86

i.p.

60/24х5

63*

60*

52*

37

39

41

23*

0

100/2 × 96

53*

53*

49*

47*

36

47*

27*

0

120/2 × 96

61*

73*

68*

61*

66*

67*

–

0